他们发现 TFF3 驱动 ER+MC 休眠，联合抑制 TFF3 和 CDK4/6 或可改善患者预后，值得科研人员一读。 在医学领域，肿瘤的治疗一直是一个充满挑战的课题，尤其是肿瘤休眠（tumor dormancy ... 此外，他们还利用免疫组化（IHC）技术对肿瘤组织中的蛋白表达进行定位和 ...

Dr. Sara M. Tolaney discusses breast practices associated with CDK4/6 inhibitors for the treatment of breast cancer. At the 42nd Annual Miami Breast Cancer Conference, Dr. Sara M. Tolaney sat down for ...

The Diehl lab also explores the interconnections of lipid signaling, epigenetic regulation and the role of the unfolded protein response within tumor progression. One major focus of Dr. Diehl’s ...

Among the many promising advances in breast cancer treatment in recent years are CDK4/6 inhibitors. These are targeted drugs that can be used for women with a common type of breast cancer ...

While the use of CDK4/6 inhibitors combined with endocrine therapy have significantly improved outcomes in patients with HR-positive, HER2-negative metastatic breast cancer, Pedram Razavi ...

DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a ...